NH lawmakers want antipsychotic sales probed; Sandoz recalls eye drug in Canada

> A group of New Hampshire legislators petitioned their attorney general to launch a criminal investigation of several drugmakers that market antipsychotic meds. Report

> Sandoz, the generics arm of Novartis, is recalling its Timolol prescription eyedrops in Canada because they may contain too much active ingredient. Report

> GlaxoSmithKline will pay its Relenza partner $19 million to settle a lawsuit in which Biota accused GSK of inadequately promoting and marketing  the drug. Report

> Amgen's Enbrel injected into the spine of 12 Alzheimer's patients produced rapid improvements in verbal fluency in an uncontrolled trial, researchers said. Report

> India's Dr. Reddy's Laboratories posted a 26 percent drop in first-quarter net profit, as higher costs and expenses offset a 25 percent rise in revenue. Report

> TheStreet's Adam Feuerstein rated Gilead Science's second quarter numbers "uninspiring," with strong top-line results and a disappointment in earnings. Report

> A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a study conducted there. Report

> PTC Therapeutics has been on a roll over the last few months. But the biotech hit a loud bump when the New York Times featured the story of one mother's legal fight to gain access to PTC124 for her son, who suffers from Duchenne muscular dystrophy. Report

> Canada's MDS is slashing 210 jobs at its MDS Pharma Services and MDS Analytical Technologies divisions and is writing down the value of a Montreal facility. MDS report

> Interested in a government career devoted to drug development? Check out the FDA. The agency says it will launch a new, two-year fellowship program aimed at physicians, chemists and other pros who would like to come on board. FDA report

Emerging Drug Developer: VLST

And Finally... How, exactly, did Wal-Mart become the new FDA? Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.